Table 2.
Current clinical trials of the potential therapeutic agents that target the Wnt/β-catenin pathway
| Name | Company | Target | Agent Type | Disease | Clinical Phase |
|---|---|---|---|---|---|
| OMP18R5 (vantictumab) | OncoMed Pharmaceuticals | frizzled | Biologic agents | Solid tumors | Open-label Phase 1 dose escalation study |
| OMP-54F28 | OncoMed Pharmaceuticals/ Bayer | Wnt | Biologic agents | Solid tumors | Phase I |
| LGK974 | Novartis Pharmaceuticals | Porcupine | Small Molecule | Melanoma, breast cancer and pancreatic adenocarcinoma | Phase I |
| CWP232291 | JW Pharmaceutical | β-catenin | Small Molecule | acute myeloid leukemia | Phase I |
| PRI-724 | Prism/Eisai pharmaceuticals | β-catenin/CBP | Small Molecule | advanced myeloid malignancies | Open-Label Phase 1 dose escalation study |